Sunrest Lifescience Ltd.
SUNREST.NS
National Stock Exchange of India35.60
INR
- -
- -
Sunrest Lifescience Ltd.
SUNREST.NS
(National Stock Exchange of India)
Recent
price
35.60
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Sunrest Lifescience Ltd. (SUNREST.NS) markets and distributes over-the-counter (OTC) pharmaceutical and personal care products in India. The company offers a diverse portfolio spanning tablets, capsules, soft gels, syrups, dry syrups, ointments, creams, powders, gels, mouthwashes, solutions, suspensions, and toothpastes across therapeutic categories including anti-bacterials, antibiotics, anti-amoebics, anti-fungals, analgesics, neuropathy treatments, anti-hypertensives, anti-inflammatories, anti-ulcerants, anti-cold and anti-cough remedies, anti-allergics, nutritionals, multivitamins, multimineral nutraceuticals, anti-diarrheals, anti-malarials, anti-diabetics, dental care, anti-protozoals, anti-histamines, anti-lipidemic drugs, anti-parasitics, Ayurvedic formulations, and cosmetics. It primarily sources products from third-party manufacturers, including a 9.90% equity stake in Trilend Pharmaceuticals Private Limited, and partners with 32 manufacturers across India to serve wholesalers and retailers. Founded in 2017 and headquartered in Ahmedabad, Gujarat, the company began operations in its home state before expanding to Maharashtra in 2018 and Rajasthan in 2019, establishing a distribution network exceeding 250 distributors and 25,000 retailers supported by over 130 sales representatives. Sunrest Lifescience operates within the healthcare and pharmaceuticals industry, targeting OTC generic and branded products for general consumer markets in these regions. In recent developments, the company converted from a private limited entity to a public limited company in March 2023, enabling its initial public offering on the NSE Emerge platform to fund market expansion and operational growth. It shifted its registered office within Ahmedabad in August 2025 to support ongoing scalability. Financially, Sunrest Lifescience reported revenue growth to INR 33.12 crore for the fiscal year ended March 2025, with profits of INR 2.00 crore, reflecting compounded sales growth of 12% over the trailing twelve months despite high debtor days of 165. No major acquisitions, partnerships, or new product launches were announced in the last 1-2 years, with focus remaining on enhancing distribution and product portfolio efficiency.